Pharmacology of intracellular cytosine-arabinoside-5′-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 4, 2007, Pages 467-477

  Koehl, U ^a   Hollatz, G ^a   Rohrbach, E ^a   Visschedyk, K ^a   Cinatl, J ^b   Kornhuber, B ^a   Kreuter, J ^a   Mutschler, E ^a   Schwabe, D ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Center of Hygiene   (Germany)

Author keywords

Acute lymhoblastic leukemia; Ara C; Ara CTP; High pressure liquid chromatography; Pharmacokinetics

Indexed keywords

CYTARABINE DERIVATIVE; CYTOSINE ARABINOSIDE 5' TRIPHOSPHATE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; LEUKEMIA CELL; LYMPHOCYTE; NEWBORN; PEDIATRICS; PRIORITY JOURNAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CELL LINE; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTARABINE; HALF-LIFE; HUMANS; INFANT; INHIBITORY CONCENTRATION 50; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOCYTES; RECURRENCE;

EID: 34447538325     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0386-3     Document Type: Article

References (61)

1. Abe I, Saito S, Hori K, Suzuki M,Sato H (1982) Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res 42:2846-2851
2. Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS (1987) Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res 47:6786-6792
3. Bhalla K, MacLaughlin W, Cole J, Arlin Z, Baker M, Graham G, Grant S (1987) Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity. Blood 70:568-571
4. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710-1717
5. Boos J (1991) A simple isocratic ion-pair high-performance liquid chromatographic determination of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate for intracellular drug-monitoring and in vitro incubation assays. J Pharm Biomed Anal 9:47-52
6. + haemopoietic stem cells in their metabolism of cytosine arabinoside. Br J Haematol 105:388-393
7. Buchner T, Hiddemann W, Berdel W, Wormann B, Loffler H, Schoch C, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Andreesen R, Balleisen L, Haase D, Eimermacher H, Aul C, Rasche H, Uhlig J, Gruneisen A, Reis HE, Hartlapp J, Hirschmann WD, Weh HJ, Pielken HJ, Gassmann W, Sauerland MC, Heinecke A (2001) Remission induction therapy: the more intensive the better? Cancer Chemother Pharmacol 48(Suppl 1):S41-S44
8. Camiener GW, Smith CG (1965) Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol 14:1405-1416
9. Chabner BA, Johns DG, Coleman CN, Drake JC, Evans WH (1974) Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest 53:922-931
10. Chen TR (1977) In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104:255-262
11. Cooper T, Ayres M, Nowak B, Gandhi V (2005) Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 55:361-368
12. Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui CH, Rubnitz JE, Stewart CF, Ribeiro RC (2002) Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 20:4217-4224
13. Elgie AW, Sargent JM, Alton P, Peters GJ, Noordhuis P, Williamson CJ, Taylor CG (1998) Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res 22:373-378
14. Estey E, Plunkett W, Dixon D, Keating M, McCredie K, Freireich EJ (1987) Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1:580-583
15. Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W (1990) Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4:95-99
16. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H (2005) Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940-947
17. Freund A, Rossig C, Lanvers C, Gescher A, Hohenlochter B, Jurgens H, Boos J (1999) All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation. Ann Oncol 10:335-338
18. Frewin RJ,Johnson SA (2001) The role of purine analogue combinations in the management of acute leukemias. Hematol Oncol 19:151-157
19. Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A, Cros E, Dumontet C (2002) In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117:860-868
20. Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124
21. Gandhi V, Estey E, Keating MJ, Chucrallah A,Plunkett W (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256-264
22. Gandhi V, Estey E, Du M, Keating MJ, Plunkett W (1997) Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 3:1539-1545
23. Gandhi V, Xu YZ, Estey E (1998) Accumulation of arabinosyluracil 5′-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin Cancer Res 4:1719-1726
24. Herzig RH (1996) High-dose ara-C in older adults with acute leukemia. Leukemia 10(Suppl 1):S10-11
25. Hiddemann W, Schleyer E, Unterhalt M, Zuhlsdorf M, Rolf C, Reuter C, Kewer U, Uhrmeister C, Wormann B, Buchner T (1992) Differences in the intracellular pharmacokinetics of cytosine arabinoside (Ara-C) between circulating leukemic blasts and normal mononuclear blood cells. Leukemia 6:1273-1280
26. Huang P, Plunkett W (1995) Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181-188
27. Hubeek I, Litvinova E, Peters GJ, Broekhuizen R, Haarman EG, Huismans DR, Cloos J, Zwaan CM, Fleischhack G, Creutzig U, Kaspers GJ (2004) The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. Int J Oncol 25:1823-1829
28. Hubeek I, Peters GJ, Broekhuizen R, Zwaan CM, Kaaijk P, van Wering ES, Gibson BE, Creutzig U, Janka-Schaub GE, den Boer ML, Pieters R, Kaspers GJ (2006) In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. Haematologica 91:17-23
29. Jamieson GP, Snook MB, Wiley JS (1990) Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leuk Res 14:475-479
30. Kohl U, Schwabe D, Montag E, Bauer S, Mieth B, Cinatl J, Cinatl J Jr, Rohrbach E, Mainke M, Weissflog A et al. (1995) Formation of cytosine arabinoside-5′-triphosphate in different cultured lymphoblastic leukaemic cells with reference to their drug sensitivity. Eur J Cancer 31A:209-214
31. Mantovani L, Hasenclever D, Krahl R, Ponisch W, Herold M, Pasold R, Fiedler F, Dolken G, Kampfe D, Schmoll HJ, Subert R, Kubel M, Niederwieser D, Helbig W (2002) Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. Leuk Lymphoma 43:265-274
32. Momparler RL, Fischer GA (1968) Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem 243:4298-4304
33. Momparler RL, Onetto-Pothier N, Bouffard DY, Momparler LF (1990) Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells. Cancer Chemother Pharmacol 27:141-146
34. Moricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M (2005) Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 217:310-320
35. Muus P, Drenthe-Schonk A, Haanen C, Wessels H, Linssen P (1987) In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells. Leuk Res 11:319-325
36. Naito K, Ohnishi K (2005) [Current and new therapeutic strategies in acute myeloid leukemia]. Gan To Kagaku Ryoho 32:292-296
37. Noordhuis P, Kazemier KM, Kasperrs GJ, Peters GJ (1996) Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L- aspartate in human leukemic blast cells and cell lines. Leuk Res 20:127-134
38. Ochs J, Sinkule JA, Danks MK, Look AT, Bowman WP, Rivera G (1984) Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia. J Clin Oncol 2:1092-1097
39. Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, Muus P, Selleslag D, van der Holt B, Delforge M, Lowenberg B, Verhoef GE (2004) The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 103:2908-2913
40. Peters WG, Colly LP, Willemze R (1988) High-dose cytosine arabinoside: pharmacological and clinical aspects. Blut 56:1-11
41. Plagemann PG, Marz R, Wohlhueter RM (1978) Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Res 38:978-989
42. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ (1985) Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12:20-30
43. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ (1987) Saturation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 47:3005-3011
44. Plunkett W, Liliemark JO, Estey E, Keating MJ (1987) Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 14:159-166
45. Preisler HD, Rustum YM, Azarnia N, Priore R (1987) Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside. Cancer Chemother Pharmacol 19:69-74
46. Rayappa C, McCulloch EA (1993) A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside. Leukemia 7:992-999
47. Riva CM, Rustum YM, Preisler HD (1985) Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C). Semin Oncol 12:1-8
48. Rustum YM,Preisler HD (1979) Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 39:42-49
49. Rustum YM, Raymakers RA (1992) 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol Ther 56:307-321
50. Rustum YM, Slocum HK, Wang G, Bakshi D, Kelly E, Buscaglia D, Wrzosek C, Early AP, Preisler H (1982) Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment. Med Pediatr Oncol 10(Suppl 1):33-43
51. Schiller M, Hohenlochter B, Schulze-Westhoff P, Zimmermann M, Ritter J, Jurgens H, Boos J (1996) [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. Klin Padiatr 208:151-159
52. Schrappe M (2004) Evolution of BFM trials for childhood ALL. Ann Hematol 83(Suppl 1):S121-123
53. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E, Riehm H (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14:2205-2222
54. Seymour JF, Huang P, Plunkett W, Gandhi V (1996) Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res 2:653-658
55. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R (2003) Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101:1270-1276
56. Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M (1993) Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 72:2155-2160
57. Tanaka M, Yoshida S (1987) Formation of cytosine arabinoside-5′- triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity. Jpn J Cancer Res 78:851-857
58. Tausch W, Thom R, Odenwald E, Riehm H (1977) [Differential diagnosis of acute leukemia in childhood by means of electronic cell-volume determination]. Monatsschr Kinderheilkd 125:563-565
59. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR (1985) Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 75:632-642
60. Yamauchi T, Kawai Y, Kishi S, Goto N, Urasaki Y, Imamura S, Fukushima T, Yoshida A, Iwasaki H, Tsutani H, Masada M, Ueda T (2001) Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses. Jpn J Cancer Res 92:546-553
61. Zittoun J, Marquet J, David JC, Maniey D, Zittoun R (1989) A study of the mechanisms of cytotoxicity of Ara-C on three human leukemic cell lines. Cancer Chemother Pharmacol 24:251-255